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Targeting Acidic Diseased Tissues by
pH-Triggered Membrane-Associated
Peptide Folding
Yana K. Reshetnyak1* , Anna Moshnikova1, Oleg A. Andreev1 and Donald M. Engelman2
1 Department of Physics, The University of Rhode Island, Kingston, RI, United States, 2 Department of Molecular Biophysics
and Biochemistry, Yale University, New Haven, CT, United States
The advantages of targeted therapy have motivated many efforts to find distinguishing
features between the molecular cell surface landscapes of diseased and normal cells.
Typically, the features have been proteins, lipids or carbohydrates, but other approaches
are emerging. In this discussion, we examine the use of cell surface acidity as a feature
that can be exploited by using pH-sensitive peptide folding to target agents to diseased
cell surfaces or cytoplasms.
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INTRODUCTION
Targeting therapeutic agents to diseased tissues can significantly enhance their efficacy by reducing
side effects. Successful molecular targeting approaches have usually been based on distinguishing
the cells in a diseased tissue from those in a healthy tissue by exploiting surface features. The
advantages of targeted therapy have motivated searches for distinguishing features between the
molecular cell surface landscapes of diseased and normal cells. In this discussion we emphasize an
alternative for targeting: cell surface acidity.
Traditional approaches for targeting diagnostic and therapeutic molecules to the site of disease
are based on recognition of overexpressed receptors or specific antigens localized at the surface or
within cellular membranes (Even-Desrumeaux et al., 2011; Boonstra et al., 2016). However, variable
expression of these markers presents difficulties, and, for example, in traditional targeting to treat
tumors using molecular biomarkers, resistance by clonal selection often emerges, and compromises
the therapy (Marusyk and Polyak, 2010; Gillies et al., 2012; Greaves and Maley, 2012). Moreover,
cells in healthy tissues typically express the same proteins, reducing the specificity of targeting.
A very different set of targeting approaches might be based on the recognition of differences
in other properties of the cellular membranes in normal and diseased tissues. It has been shown
that cancer cells are mechanically softer than normal cells, and that the membranes of cancer cells
have increased fluidity (Sherbet, 1989; Schierbaum et al., 2017; Rudzka et al., 2019). Further, bilayer
asymmetry differs between normal and cancer cells, with phosphatidyl ethanolamine appearing
in larger quantities in the outer monolayer (Tan et al., 2017). With abnormally high rates of cell
division, cancer cells often exhibit such changes in membrane composition and asymmetry as
they must upregulate biosynthetic pathways to provide cell building blocks, such as membrane
components, rather than relying on circulating supplies. Membrane physical properties might
potentially be utilized for selective targeting of diseased tissues and/or the cellular uptake of various
delivery agents if means can be discovered to do so.
In addition to the targeting of biomarkers or membrane properties, cells within diseased tissues
have pronounced surface acidity resulting from their metabolism. Such acidity can be specifically
targeted by pH-triggered membrane-associated peptide folding, which is the subject of this review.
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MEMBRANE-ASSOCIATED FOLDING
The process of peptide insertion to span a membrane is of
fundamental interest in evolution. It also illuminates our thinking
about the ways that lipid interfacial regions can interact with
the molecules they encounter (White et al., 2001). Membrane
protein insertion and folding is facilitated by complex molecular
machines in vivo, such as the translocon, which assist in
placing transmembrane sequences across the bilayer (Cymer
et al., 2015). Some moderately polar transmembrane domains
can postranslationally translocate themselves into membranes.
For example, C terminally anchored proteins, such as the
apoptotic repressor Bcl-xL, can insert their C-terminal ends into
membranes (Steel et al., 2002; Habib et al., 2003; Vargas-Uribe
et al., 2013). Another example is the spontaneous insertion of
diphtheria toxin triggered by low pH (Donovan et al., 1982;
O’Keefe et al., 1992; Ladokhin, 2013; Vargas-Uribe et al., 2015).
Studies of examples of spontaneous insertion and folding have
inspired the design of synthetic peptides that are soluble in
aqueous solution and spontaneously insert into membranes, and
have been the subjects of biophysical investigations (Ladokhin
and White, 2004). The discovery of peptides that respond to low
pH by spontaneously inserting and folding across a membrane
(Hunt et al., 1997) accelerated the development of these peptides
for medical applications (Reshetnyak et al., 2006; Andreev
et al., 2014; Wyatt et al., 2018a), as it emerged that low cell
surface pH (or high acidity) is associated with several significant
pathological conditions.
ACIDITY IN DISEASED TISSUES
An elevated level of extracellular acidity is found in tissues
in pathological states such as cancer, inflammation (including
neuro-inflammation), arthritis, stroke, ischemia, and others
(Menkin and Warner, 1937; Reeh and Steen, 1996; Kedika et al.,
2009; Pezzulo et al., 2012; Robbins and Swanson, 2014; Vidale
et al., 2017; Pillai et al., 2019). In the case of ischemia and
stroke, hypoxia and a compromised blood supply are primarily
associated with the pathology; the cellular metabolism in these
diseased tissues becomes partially anaerobic, leading to the
production of acid from glycolysis (the Pasteur effect) (Krebs,
1972). An additional effect is found in malignant cancers and
activated macrophages, which have an elevated uptake of glucose
even with a normal oxygen supply, known as “aerobic glycolysis”
or the Warburg effect (Warburg et al., 1927; Warburg, 1956).
These cells continue to use glycolysis at a high rate, even
when mitochondrial oxidative pathways are available, resulting
in acidification that adds to any result of hypoxia (Swietach,
2019). Further, the production of carbon dioxide by the rapidly
metabolizing cells causes expression of carbonic anhydrases
on the cancer cell surfaces, promoting further acidification of
the extracellular environment as the cells export the carbon
dioxide and the anhydrases convert it into bicarbonate ions
and protons (Wykoff et al., 2000; Potter and Harris, 2003;
Swietach et al., 2009). Finally, the electrochemical potential across
a cell membrane is positive on the outside of the cell, and
will tend to concentrate hydrated protons and other cations
near the surface.
The cytoplasmic production of acidity is deleterious, so cells
have mechanisms to regulate their cytoplasmic pH by exporting
the acidity to the extracellular environment. pH regulation is
carried out by transmembrane proteins that pump protons from
the cytoplasm across the plasma membrane to the extracellular
space or to the lumen of various organelles (Damaghi et al., 2013).
The flux of exported acidity lowers the pH surrounding a diseased
cell, and the proton concentration is accentuated near the cell
surface both by the flux and by the membrane electrochemical
potential. As a result, the extracellular pH is lowest at the surfaces
of diseased cells, where it is significantly lower than normal
physiological pH and the bulk extracellular pH (Anderson et al.,
2016). The low pH region persists at the cell surface even in well-
perfused areas within diseased tissue (Gillies et al., 2012). The
acidity on the surfaces of cells is a targetable characteristic that
is not subject to clonal selection, and the level of acidity is a
predictor of disease progression (Estrella et al., 2013).
pHLIPr TECHNOLOGY
pH Triggered Insertion Into Membrane
and Folding
pH (Low) Insertion Peptides (pHLIPs) utilize pH-triggered
membrane insertion and folding to target acidic diseased tissues.
The insertion can be used for the selective delivery of therapeutic
and imaging agents (Wyatt et al., 2018a). pHLIPs constitute
a large class of moderately hydrophobic membrane peptides
that are soluble in aqueous solution at normal and high pHs.
These peptides mainly consist of combinations of non-polar
residues and negatively charged, protonatable residues (such as
Asp and Glu, and their analogs) (Musial-Siwek et al., 2010;
Weerakkody et al., 2013; Onyango et al., 2015). The presence
of hydrophobic residues promotes adsorption to bilayer surfaces
in most types of cellular membranes, and the adsorption is
associated with a release of energy, mainly from hydrophobic
interactions (Reshetnyak et al., 2008). pHLIPs containing fewer
hydrophobic residues have lower affinities for membranes and
much faster blood clearance (Weerakkody et al., 2013; Demoin
et al., 2016). In addition, peptide adsorption to the membrane
is modulated by membrane composition (Kyrychenko et al.,
2015; Karabadzhak et al., 2018; Vasquez-Montes et al., 2018) and
the local ionic environment (Schlebach, 2019; Vasquez-Montes
et al., 2019; Westerfield et al., 2019). Significant attention has
been given to the conformational states of pHLIPs adsorbed by
membranes (Brown et al., 2014; Gupta et al., 2018; Vasquez-
Montes et al., 2018). Such studies are challenged by the fact
that pHLIPs do not adopt unique structures at the membrane
surfaces, and a large variety of conformations is possible and
dependent on individual pHLIP sequences (Wyatt et al., 2018b)
or lipid compositions (Kyrychenko et al., 2015; Vasquez-Montes
et al., 2018). No significant membrane distortion is created
when pHLIPs partition into a bilayer outer leaflet in their non-
helical unstructured forms (Narayanan et al., 2016), in contrast
to amphiphilic pore-forming peptides, which partition into one
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leaflet of a bilayer as rigid alpha-helicies, inducing significant
membrane tension and promoting membrane destabilization
(Kornmueller et al., 2016; Masuda et al., 2019).
When the extracellular pH is low, key Asp/Glu residues
are protonated, and the overall hydrophobicity (LogP) of the
peptide is enhanced. Because the dielectric environment affects
the protonation and deprotonation rates, the pKas of the
carboxyl groups are raised in the environment of the membrane
surface (Harris and Turner, 2002), usefully shifting them to
physiologically relevant values near 6.0. Protonaton shifts the
equilibrium and promotes peptide partitioning more deeply
into the bilayer, which in turn triggers a coil-helix transition
(folding) as the peptide backbone finds itself in a lower
dielectric environment, favoring the systematic formation of
intrahelical hydrogen bonds and a helical conformation (Popot
and Engelman, 2000). The process is reversible: if the pH is raised,
the exit of the peptide from the membrane induces unfolding
(Andreev et al., 2010; Karabadzhak et al., 2012). The formation
of helical structure at the surface of the membrane leads to
membrane bilayer perturbation that promotes transmembrane
insertion, relaxing the tension as the peptide adopts a stable
transmembrane helical orientation. Kinetics studies (Andreev
et al., 2010; Karabadzhak et al., 2012) and constant-pH molecular
dynamics simulations (Vila-Vicosa et al., 2018) have provided
insights into the peptide insertion and exit pathways. Thus, there
is a reasonable set of concepts underlying the mechanism of pH
sensing and insertion.
While there may be some agreement concerning the overall
concepts discussed above, there is an area in which we believe
there is an important conceptual misunderstanding found in the
literature in the interpretation of protonation events, polypeptide
partitioning and folding in a membrane and the targeting and
intracellular delivery within a biological system. We assert:
• At each pH, an ensemble of all pHLIP states exists. At
high and low pHs the predominant, but still not unique,
states are the peptide membrane-adsorbed, and membrane-
inserted states, respectively, each of which has a variety of
dynamic excursions but is approximately described by the
two states (Reshetnyak et al., 2007). At intermediate pHs
a more distributed mixture of states is present. Therefore,
any assumption of a sequential progression of intermediates
from the membrane-adsorbed to the membrane-inserted
state (Otieno et al., 2018) is a simplified view, which does
not reflect the complexity of thermodynamic ensembles in
real physical systems.
• The shift of the equilibrium from one distribution of states
to another is triggered by pH changes in the environment
near the lipid bilayer: a drop of pH induces protonation
of Asp/Glu residues and the C-terminus. The pKa of
protonation of each individual COO− groups is dependent
on the electrostatic potential, which varies dynamically
with the ion concentrations, membrane composition and
peptide insertion depth, as well as the presence of other
groups dictated by the local dynamics of the peptide.
Therefore, the pKa of any individual group is constantly
changing in both directions while the average of the
pHLIP ensemble of states propagates more deeply into
the membrane (Vila-Vicosa et al., 2018). No fixed value
of pKa can be assigned to any individual Asp/Glu
residue or C-terminus during the course of insertion
(Scott et al., 2017).
• The presence of positive charges at the peptide N-terminus
and/or Arg residue at the N-terminal part, which are
energetically costly to partition across a membrane barrier
(Vila-Vicosa et al., 2018), predetermines the probable
directionality of pHLIP insertion into the membrane,
placing C-terminal end in, and the direction of the exit into
the extracellular space (Karabadzhak et al., 2012).
• Since the insertion kinetics show timescales of ms to sec for
the process (Karabadzhak et al., 2012), it is difficult to know
which lipid bilayer organizational changes may accompany
the insertion. Accurate dynamic modeling is problematical
on this timescale, and results (Deng et al., 2013; Kong et al.,
2014) should be regarded with caution.
• As noted above, in a biological system having living cells in
acidic diseased tissues, a pH gradient exists in the vicinity
of the cell membrane: at the cell surface the pH can be
around 6.0 and it increases with distance from the cell
surface (Stock et al., 2007; Anderson et al., 2016; Wei et al.,
2019). Thus, the bulk extracellular pH is higher than the cell
surface pH. The cell surface pH is relatively independent
of tissue perfusion and will be low in both poorly and
well perfused areas. Since pHLIPs sense pH at cell surfaces,
where it is the lowest, an increase in the population of the
membrane-inserted state is promoted.
• Living cells maintain electrochemical potential gradients
across their membranes with the positive charge on the
outside surfaces. The intracellular pH is about 7.3 in both
healthy and diseased cells (Swietach, 2019), so the part of
the potential that arises from a pH difference reverses as the
external pH of a normal cell (∼7.4) is changed to∼6.0. The
Asp/Glu residues and the C-terminus at the membrane-
inserted end of pHLIPs will be protonated as they insert
across the membrane, but once in the cytoplasm they will
be largely deprotonated in the cytoplasm. The resulting
charges lead to an “anchoring effect,” in which the rate of the
translocation of the charged COO− groups back across the
membrane is orders of magnitude lower compared to the
rate of translocation in their neutral, non-charged COOH
form (Kornmueller et al., 2016). Thus, there is a bias toward
accumulation of the membrane-inserted state.
• Thermodynamic equilibration is not limiting either for
pHLIP insertion into membranes or for the intracellular
delivery of many polar cargoes. Given enough time
for equilibration, even polar or charged cargoes will be
delivered into cells and trapped in the cytoplasm if they
are released from a pHLIP. However, in a living biological
system there are limiting factors that come into play,
including the circulation of the external medium, the
normal turnover of the membrane via endocytosis, changes
during growth and cell division, etc., so there are limits
on cargo delivery based on the kinetic requirements of
the insertion process, which may be very slow. Thus, the
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kinetics of insertion becomes a key factor for targeting and
cargo delivery.
Targeting and Extracellular Delivery of
Cargo Molecules
Peptides of the pHLIP family are members of the class of
membrane-inserting peptides: they insert across lipid bilayers,
leaving one terminus in the extracellular space and translocating
the other one into the cytoplasm (Andreev et al., 2007; Thevenin
et al., 2009). A variety of cargo molecules might be attached to the
membrane non-inserting end to target them to acidic cell surfaces
(Figure 1). As might be expected, there are few constraints on
which cargoes can be targeted in this way. Examples of useful
cargoes include imaging and immuno-stimulating agents. In
addition to the delivery of small molecules, pHLIPs can direct a
variety of nanoparticles and nanomaterials to the site of disease,
which has been the subject of numerous publications including
review articles (Han et al., 2013; Pereira et al., 2015), but is beyond
the scope of this review.
Imaging agents coupled to pHLIPs have been used in animal
models to label primary tumors, metastatic lesions and other
acidic pathological states (Andreev et al., 2007; Reshetnyak
et al., 2011; Daumar et al., 2012; Macholl et al., 2012; Sosunov
et al., 2013; Weerakkody et al., 2013; Adochite et al., 2014;
Cruz-Monserrate et al., 2014; Tapmeier et al., 2015). pHLIP-
based PET (positron emission tomography) and fluorescent
imaging agents are now on their way to human clinical trials.
18F-NO2A-pHLIP is a PET agent for imaging tissue acidity
(Demoin et al., 2016), which will be administrated to breast
cancer patients in a phase I clinical trial, and other PET isotopes
such as 64Cu and 89Zr, might be used if longer half-lives
would be desirable. The PET-pHLIP agents are expected to
have applications in the imaging of a variety of tumors, and
might also potentially prove to be useful for the diagnosis of
brain tumors, where FDG is challenging to employ due to
the high uptake of glucose by the normal brain. Applications
in the imaging of other acidic diseased states, such as severe
FIGURE 1 | Targeted pHLIP delivery of cargoes to acidic cell surfaces. The
cargo-pHLIP construct does not accumulate in healthy tissue cells with
normal cell-surface pH (pH = 7.4) (left), since the pHLIP does not insert. The
low pH (6.0–6.5) at the surface of a diseased cell causes pHLIP to insert
across lipid bilayer to form a stable transmembrane helix, positioning the
cargo at the surface (right). Examples of useful cargoes include imaging and
immuno-stimulating agents, such as fluorescent dyes or antigens.
inflammation, atherosclerotic plaques, or arthritis, might also be
developed. A PET-pHLIP agent potentially could have utility in
the clinic for the recruitment of patients for treatment and to
follow the effects of cancer therapy in general, and especially,
immunotherapy. For example, the function of T-cells is inhibited
by low pH (Huber et al., 2017) and potentially, immuno-therapy
outcomes might be predicted, modeled and monitored using a
PET-pHLIP imaging agent.
In another imaging application, a fluorescent agent has
been developed using ICG, an indocyanine near infrared (NIR)
fluorescent dye widely used for circulatory imaging (Desmettre
et al., 2000; Alander et al., 2012). ICG-pHLIP is expected to
be given as a single intravenous injection for tumor targeting
and identification of margins and micrometastasis in the vicinity
of primary tumors to improve surgical resections (Golijanin
et al., 2016; Brito et al., 2019). To target and visualize tumors,
imaging will be performed 24 h after IV injection of ICG-
pHLIP to ensure blood and tissue clearance of the agent that
is not bound in tumors, optimizing the contrast for marking
cancerous lesions. It is important to note that the fluorescence
is enhanced about 15–16 times compared to the emission in
solution when pHLIP positions the ICG next to the membrane
lipid bilayer (Golijanin et al., 2016; Roberts et al., 2019), thus
providing additional enhancement of the tumor to background
ratio. ICG-pHLIP can be easily adopted in clinical practice, since
many clinical imaging systems for recording of ICG fluorescence
are developed and currently in use in hospitals (Av et al., 2016;
Nagaya et al., 2017).
Since the ICG-pHLIP resides in the blood for hours, imaging
applications for angiography may also be useful. ICG-pHLIP
interacts with blood proteins and remains circulating in the
blood, allowing excellent visualization of blood vessels for a
period of time of 1–2 h as compared to minutes for ICG
alone. Blood flow imaging has wide ranging applications in a
variety of surgical procedures (Desmettre et al., 2000; Alander
et al., 2012), and has motivated the development of the imaging
systems noted above.
A different, promising imaging agent is QC1-pHLIP (Roberts
et al., 2019), where QC1 is a quencher molecule (as opposed to
ICG, which is an emitter). QC1 is designed to effectively absorb
light and transfer it into heat, which makes it an excellent agent
for photo-acoustic imaging. Photo-acoustic imaging is a rapidly
developing imaging modality (Valluru et al., 2016; Schellenberg
and Hunt, 2018) and QC1-pHLIP could be a promising candidate
for clinical translation for pre-operative imaging.
Animal studies have also demonstrated the potential utility of
pHLIP linked to paramagnetic and superparamagnetic iron oxide
nanoparticles for MRI, chitosan capped mesoporous silica coated
gold nanorods and gold nanostars for computed tomography,
photoacoustic imaging, and photothermal therapy (Janic et al.,
2016; Zeiderman et al., 2016; Tian et al., 2017; Wei et al., 2017).
Importantly, in addition to the extracellular delivery
of imaging agents, a variety of other cargoes, such as
immuno-stimulating molecules including proteins (cytokines),
carbohydrates, peptides (like HA-peptide), or small molecule
antigens [such as 2,4-dinitrophenyl (DNP) and others] can
be specifically targeted to the surfaces of tumor cells to
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induce biological responses. Specific antigens to activate either
endogenous or exogeneous antibodies could be positioned
on tumor cell surfaces by pHLIP, bypassing the need to
identify molecular biomarkers for targeting. Endogenous
antibodies could be developed against the targeted antigen
by immunization. Or, exogenous antibodies or antibody drug
conjugates (ADCs) could be administrated to target specific
antigens delivered to tumor cells by pHLIP.
Targeting and Intracellular Delivery of
Cargo Molecules
The pHLIP technology can also be used for the targeted
intracellular delivery of molecules by connecting them to the
inserting end of the peptide by linkers cleavable in cytoplasm,
such as S-S links (Figure 2). If the cargo needs to be released
in the cytoplasm in its original, non-modified form (as in the
case of some small molecules) to prevent losing affinity to
its intracellular target, self-immolating linkers could be used.
Self-immolative elimination is a spontaneous and irreversible
FIGURE 2 | Targeted pHLIP delivery of cargoes to the cytoplasm. The
pHLIP-cargo construct does not insert into cells with normal surface pH
(pH = 7.4), but engages in transient binding that samples the surface pH and
is then washed away (left). If the cell-surface pH is low (pH∼6.0–6.5), pHLIP
samples the pH and inserts across the lipid bilayer, translocating the cargo
directly into the cytoplasm (right). By using a link that is stable in the blood but
cleavable in the cytoplasm, the cargo can be released inside the cell.
disassembly of a multicomponent compound into its constituent
fragments through a cascade of electronic elimination processes.
If a cargo can be released in cytoplasm in slightly modified
form (as in the case of PNA or amanitin cargoes) a simple
S-S linker (for example, SPDP crosslinker) can be used. It is
important to note that the linker or additional modulators
can facilitate the intracellular delivery of cargoes by lowering
the effective membrane barrier (An et al., 2010; Wijesinghe
et al., 2011; Moshnikova et al., 2013). If a cargo is polar,
the hydrophobic linker/modulator may increase the LogP of
the cargo-modulator. If the cargo is hydrophobic, a polar
linker/modulator may decrease the LogP of the cargo-modulator
to restrict off-target insertion.
Membrane-associated folding facilitates the cooperative
translocation (flipping) of cargoes across the membrane bilayer
directly into the cytoplasm, bypassing endocytotic uptake
(Reshetnyak et al., 2006; An et al., 2010; Wijesinghe et al.,
2011; Moshnikova et al., 2013). This pathway significantly
expands the practical range of the molecular properties that can
be used in pharmacological agents. Figure 3 summarizes the
properties of cargo molecules best suited for pHLIP intracellular
delivery. These range from polar or negatively charged cell-
impermeable molecules to moderately hydrophobic molecules,
including molecular weights from a few hundred Daltons to
several kDa. The possible use of polar therapeutic cargoes
presents a significant advantage for reduction off targeting and
toxicity, since such molecules will not be able to enter cells on
their own, and, once delivered, they will not readily exit the
cell being targeted.
Peptide nucleic acids (PNAs) belong to such a class of useful,
cell-impermeable polar molecules, which can activate immune
responses and regulate cell functions by targeting coding and
non-coding RNAs and DNA (Nielsen et al., 1991). PNA was
one of the first polar molecules translocated into cells by pHLIP
(Reshetnyak et al., 2006), followed by examples demonstrating
in vivo targeting of miRNAs, long non-cording RNAs, and
mRNAs (Cheng et al., 2015; Ozes et al., 2017; Zhao et al.,
2018; Price et al., 2019; Sahraei et al., 2019). An especially
FIGURE 3 | Some of the chemical properties of cargo molecules that can be targeted and delivered into cells by pHLIP. Two scales are shown, one representing the
charges on a cargo and the other the Log of the Octanol-Water partition coefficient (LogP). Delivery by pHLIP is feasible for large, polar molecules that do not enter
cells by themselves, expanding the range of pharmacology beyond that normally expected for drugs and attenuating leakage of the cargo from the cell after release.
Some negative charge is acceptable, but positive charges slow the kinetics significantly. Moderately polar drugs can also be targeted, but very hydrophobic
molecules disturb the insertion selectivity of pHLIP by adding hydrophobic membrane interactions and facilitating insertion at less acidic pHs.
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attractive idea is to deliver a PNA to downregulate miR-21, which
is the most commonly upregulated miRNA in solid tumors,
and is associated with tumor pathogenesis during all stages
of carcinogenesis. Tumor targeted intracellular pHLIP-mediated
delivery of PNA targeting miR-21 in cancer cells and TAMs
promotes an antitumoral immune response characterized by a
macrophage-mediated improvement of cytotoxic T cell responses
through the induction of cytokines and chemokines including
IL12 and CXCL10 (Sahraei et al., 2019). Thus, the pHLIP-
PNA immuno-stimulating effect allows the conversion of “cold”
tumors into “hot” tumors, and the stimulation might enhance
the therapeutic benefit of immuno-therapies that have already
been developed. In addition to PNAs, a variety of immune-
stimulating molecules, especially polar ones, like STING agonists,
might be very good candidates for pHLIP intracellular delivery.
In another application, the pHLIP-mediated delivery of PNA to
target miR-33 prevented the formation of fibrosis in the kidney
(Price et al., 2019).
Targeted pHLIP-mediated delivery of moderately
hydrophobic small molecule drugs has proven to be successful
as well. Among the drugs that have been delivered are
potent inhibitors of tubulin, such as monomethyl auristatin E,
poly (ADP-ribose) polymerase inhibitors (PARPi’s) including
rucaparib and talazoparib, and other molecules (Burns et al.,
2015, 2017; Song et al., 2016). A notable property is that pHLIP
delivery has been shown to reduce bone marrow accumulation
and toxicity, which is a significant issue in the use of many potent
cytotoxic molecules. Thus, it appears that pHLIP delivery can
reduce off-targeting, widen the therapeutic window and enhance
the therapeutic index, which opens an opportunity to reconsider
the use of very potent APIs for treatment of aggressive and
metastatic cancers.
Other classes of potent therapeutic small molecules, such
as the corticosteroids widely used in the treatment of severe
inflammations and infections, might be targeted to restrict
their action to the site of disease. Corticosteroids are very
effective drugs that possess immunosuppressive properties.
Dexamethasone is an example of a potent steroid with
important clinical utility, but systemic administration and
associated systemic immunosuppression are associated with
devastating side effects, limiting the dose and duration of
its uses (Johnson and Kelley, 2019). These limitations might
be significantly reduced if targeted delivery could be used to
treat inflamed tissues. pHLIPs can target inflamed tissues and
fibrotic sites (Andreev et al., 2007), most probably by targeting
activated macrophages.
Features of the pHLIP Technology
To summarize, pHLIP peptides bind to the surface of tumor
cells or cells in inflamed tissues, where the acidity is the most
pronounced, followed by folding and insertion as helices across
the membrane. Using the insertion of pHLIP, cargoes can be
located at an acidic cell surface if the cargo is attached to the
non-inserting end (extracellular delivery) and/or the cargo can
be directly delivered and released into its cytoplasm if the cargo
is attached to the membrane-inserting end via a bond that is
unstable in the cytoplasm (intracellular delivery). The following
advantages are associated with pHLIP targeted delivery:
• Cell-surface acidity and pHLIP targeting is not subject to
clonal selection.
• pHLIP targeting overcomes the problem of antigen or
other marker heterogeneity found within the tumor
and between tumors.
• pHLIP tumor targeting can reach about 20% of the ID/g.
• pHLIP binding to a cell membrane is much less
saturable than antigen binding, so larger amounts of cargo
can be delivered.
• pHLIP can provide additional protection and increased
stability of a drug in the blood by interaction with the ∼
4 kDa pHLIP unstructured polymer.
• pHLIP alters the pharmacokinetics and biodistribution of drugs.
• pHLIP reduces off targeting and toxicity, especially in bone
marrow, and can target highly potent molecules to tumors
to enhance their therapeutic index.
• pHLIP directly flips cargo into the cytoplasm bypassing
endosomal trapping.
• pHLIP’s cargo can be polar and large, reducing escape from
the targeted cell.
CONCLUSION
pHLIP technology is now taking its first steps into human
imaging clinical trials, which potentially will open an opportunity
for imaging of acidic diseased tissues, improvement of surgical
resections of tumors, and visualization of blood flow. The
initiation of imaging trials should be closely followed by the
first trials of therapeutic interventions, such as the targeted
delivery of cytotoxic and immune-stimulating or immune-
suppressive molecules.
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